Interviews with the world’s key opinion leaders in cancer

Tag2014 ASCO Genitourinary Cancers Symposium

Enzalutamide improves overall and progression-free survival in men with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer

March 6, 2014

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically...